Results 181 to 190 of about 5,304,709 (301)

Prenatal genetic testing and potential consequences. [PDF]

Med Genet
Jauch SF, Klaritsch P.
europepmc   +1 more source

The heart of genetic testing [PDF]

Journal of Small Animal Practice, 2014
openaire   +2 more sources

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Trends in awareness and uptake of genetic testing among the United States population, 2011-2022. [PDF]

J Community Genet
Naaseh A, Shi M, Tohmasi S, Linnenbringer EL, Margenthaler JA, Colditz GA, Cao Y.   +6 more
europepmc   +1 more source

The genetic testing of children [PDF]

Journal of Medical Genetics, 1995
openaire   +2 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Genetic Testing by Age at Onset in Parkinson Disease.

JAMA Neurol
Balck A, Vollstedt EJ, Westenberger A, Lange LM, Trinh J, Kasten M, Lohmann K, Brüggemann N, Trenkwalder C, Mollenhauer B, Alcalay R, Galvelis KG, Beck JC, Bauer P, Klein C, König IR, Global Parkinson’s Genetics Program (GP2), the ROPAD Study Group, and the PDGENEration Study.   +18 more
europepmc   +1 more source

Genetic testing practices across European epilepsy centers: An ERN EpiCARE survey. [PDF]

Epilepsia Open
Tchaicha S, Van Hulle J, Brilstra E, Brunklaus A, Cantalupo G, Geroldinger M, McTague A, Kälviäinen R, Turón-Viñas E, Arzimanoglou A, Møller RS, Nabbout R.   +11 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Genetic Testing Yield for Dilated Cardiomyopathy in a Single Lithuanian Center. [PDF]

Diagnostics (Basel)
Šukys M, Ereminienė E, Aleknavičienė K, Jonikas R, Mėlinytė-Ankudavičė K, Bučius P, Ugenskienė R.   +6 more
europepmc   +1 more source